Ahh interesting. At first I'd read that to mean that they weren't taking data down, and existing customers would still be able to access their reports. I figured that only applied to people who had already had a report generated.
Everyone who has ordered since November 22nd is offered a refund. The details are on the website and will come in the email. Have some faith, dude. Of course they have to do that.
- An individual for whom 23andMe correctly identified a heart issue that he later had.
- An individual who caught his prostate cancer early because 23andMe told him he was likely to have it.
In both cases, 23andMe successfully identified the condition before it occurred. That's about as close to marketing yourself as a predictor of disease as you can get. Granted, the word for word text in the video references "elevated risk", but the overall story they're selling to the public is that 23andMe predicts diseases you'll have. At least, that's my impression. Really interested to see how all this pans out.
Yes, for the mendelian ones that can be inferred in a relatively straightforward way from the raw data. Not really, for the more complicated risk assessments.
You can run the raw data through a 3rd party tool like Promethease (http://snpedia.com/index.php/Promethease) while you wait for the FDA kerfuffle to work itself out. YMMV though.
It's a chicken and egg problem. The more people like you purchase the service, the less European it will become. It has made huge strides in the last couple of years, but there is a way to go still.
